These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 10659400)

  • 1. Lerisetron. F 0930, F 0930RS.
    Drugs R D; 1999 Oct; 2(4):245-6. PubMed ID: 10659400
    [No Abstract]   [Full Text] [Related]  

  • 2. Itasetron. DAU 6215, U 98079.
    Drugs R D; 1999 Oct; 2(4):243-4. PubMed ID: 10659399
    [No Abstract]   [Full Text] [Related]  

  • 3. Zatosetron. LY 191617, LY 277359.
    Drugs R D; 1999 Oct; 2(4):253-5. PubMed ID: 10659404
    [No Abstract]   [Full Text] [Related]  

  • 4. Palonosetron. RS 25259, RS 25259 197.
    Drugs R D; 1999 Oct; 2(4):251-2. PubMed ID: 10659403
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacological effect of lerisetron, a new 5-HT3 antagonist, in rats.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    J Pharm Sci; 2002 Jan; 91(1):41-52. PubMed ID: 11782896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology and clinical experiences with serotonin (5-HT3) receptor antagonists].
    Scholz J
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1997 Oct; 32(10):626-8. PubMed ID: 9445561
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of lerisetron, a new 5-HT3 receptor antagonist, on ipecacuanha-induced emesis in healthy volunteers.
    Cooper M; Sologuren A; Valiente R; Smith J
    Arzneimittelforschung; 2002; 52(9):689-94. PubMed ID: 12404884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels.
    Jauregizar N; Calvo R; Suarez E; Quintana A; Raczka E; Lukas JC
    Pharm Res; 2001 Jun; 18(6):838-45. PubMed ID: 11474789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics.
    Morrow GR; Roscoe JA; Kirshner JJ; Hynes HE; Rosenbluth RJ
    Support Care Cancer; 1998 May; 6(3):244-7. PubMed ID: 9629877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum protein binding of lerisetron, a novel specific 5HT3 antagonist, in patients with cancer.
    Calvo R; Jiménez RM; Trocóniz IF; Suárez E; Gonzalo A; Lucero ML; Raczka E; Orjales A
    Cancer Chemother Pharmacol; 1998; 42(5):418-22. PubMed ID: 9771958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [From cocaine to innovative antiemetics. The medicinal chemistry of 5-ht3 receptor antagonists].
    Zettl H; Schubert-Zsilavecz M; Siebert CD
    Pharm Unserer Zeit; 2007; 36(5):354-61. PubMed ID: 17722162
    [No Abstract]   [Full Text] [Related]  

  • 12. Selective serotonin 5-HT3 receptor antagonists for postoperative nausea and vomiting: are they all the same?
    Gan TJ
    CNS Drugs; 2005; 19(3):225-38. PubMed ID: 15740177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3-receptor antagonists in the control of delayed-onset emesis.
    Gridelli C
    Anticancer Res; 2003; 23(3C):2773-82. PubMed ID: 12926112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-HT3 receptor antagonists vs traditional agents for the prophylaxis of postoperative nausea and vomiting.
    Loewen PS; Marra CA; Zed PJ
    Can J Anaesth; 2000 Oct; 47(10):1008-18. PubMed ID: 11032279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience with use of a selective 5HT3 receptor antagonist (ondansetron) to prevent high dose chemotherapy induced emesis.
    Parikh PM; Shah SR; Shah SC; Sheth V; Patel RA; Shah KC; Jain PK
    Indian J Cancer; 1996 Mar; 33(1):17-20. PubMed ID: 9063013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retraction Notice: Current review of ramosetron in the prevention of postoperative nausea and vomiting.
    Fujii Y
    Curr Drug Saf; 2011 Apr; 6(2):122-7. PubMed ID: 21382011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 5-HT(3)R binding of lerisetron: an interdisciplinary approach to drug-Receptor interactions.
    Parihar HS; Suryanarayanan A; Ma C; Joshi P; Venkataraman P; Schulte MK; Kirschbaum KS
    Bioorg Med Chem Lett; 2001 Aug; 11(16):2133-6. PubMed ID: 11514154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arrhythmia risk of antiemetic agents.
    Kantor GS
    Anesthesiology; 2002 Jul; 97(1):286. PubMed ID: 12131144
    [No Abstract]   [Full Text] [Related]  

  • 19. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
    Gregory RE; Ettinger DS
    Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal selection of antiemetics in children receiving cancer chemotherapy.
    Roila F; Aapro M; Stewart A
    Support Care Cancer; 1998 May; 6(3):215-20. PubMed ID: 9629872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.